Why Is IDEXX Laboratories Stock Gaining Tuesday?
IDEXX Laboratories, Inc. (NASDAQ: IDXX ) stock rose Tuesday after the veterinary diagnostics company reported second-quarter results that topped Wall Street estimates and raised its full-year earnings outlook. Companion Animal Diagnostics Fuel Growth The company reported second-quarter earnings of $4.27 per share, beating the analyst consensus estimate of $3.96. Revenue increased 10% year over year to $1.217 billion, or 9% on an organic basis, exceeding the Street estimate of $1.201 billion. Companion Animal Group revenue rose 9% to $1.118 billion, driven by an 11% increase in recurring diagnostics revenue, or 10% on an organic basis. Water segment revenue climbed 15% to $59 million, supported by strong demand in the United States and Europe. Livestock, Poultry and Dairy revenue increased 11% to $35 million, led by growth across the Americas. “Our second quarter results reflect...
IDEXX Laboratories, Inc. (NASDAQ: IDXX ) stock rose Tuesday after the veterinary diagnostics company reported second-quarter results that topped Wall Street estimates and raised its full-year earnings outlook. 96. 201 billion.
118 billion, driven by an 11% increase in recurring diagnostics revenue, or 10% on an organic basis. Water segment revenue climbed 15% to $59 million, supported by strong demand in the United States and Europe. Livestock, Poultry and Dairy revenue increased 11% to $35 million, led by growth across the Americas. “Our second quarter results reflect the strength of our Technology for Life strategy, with continued innovation across our Catalyst, Fecal Dx, and IDEXX inVue Dx platforms supporting deeper customer adoption and higher diagnostic utilization,” President and CEO Mike Erickson said.
90. 67. 76 billion. 711 billion.
Management said the revised outlook reflects continued strength in recurring Companion Animal Diagnostics revenue, improved commercial execution and expectations for higher operating margin expansion and earnings growth. Analysts Remain Constructive Despite Soft Vet Visits IDEXX placed more than 5,200 premium diagnostic instruments during the quarter, including about 1,600 InVue Dx analyzers, keeping the company on pace to meet its full-year placement target of 5,500 units. S. 3% during the quarter.
On the earnings call, management said pressure on wellness visits remained the primary headwind, while non-wellness visits posted modest growth. William Blair analyst Ryan Daniels said second-quarter results were in line with expectations despite continued weakness in veterinary visits and soft consumer sentiment. S. pet population.
Daniels also said IDEXX maintains a strong competitive position, citing industry-leading customer satisfaction and the potential for another product launch. 79 at the time of publication on Tuesday, according to Pro data. Read Also: Inflation Bites Pets: Chewy Pins Outlook Cut On 'Discerning' Consumers